![Scott Coiante](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Coiante
Director of Finance/CFO at
LEXICON PHARMACEUTICALS, INC.
Net worth: 237 051 $ as of 2026-08-30
Profile
Scott M.
Coiante is currently Chief Financial Officer & Senior Vice President at Lexicon Pharmaceuticals, Inc. since 2025.
Formerly, Mr. Coiante was Chief Financial Officer, Treasurer & Senior Vice President at Agile Therapeutics, Inc. from 2023 to 2024.
From 2019 to 2023, served as Chief Financial Officer & Senior Vice President at Aprea Therapeutics AB and as CFO, Secretary, Treasurer & Senior Vice President at Aprea Therapeutics, Inc. From 2010 to 2019, held the roles of CFO, Principal Accounting Officer & Senior Vice President at Agile Therapeutics, Inc. Between 2005 and 2010, was Treasurer, Chief Accounting Officer & VP-Finance at Medarex, Inc. Worked as Head-Financial Reporting at Ernst & Young LLP from 1989 to 2000.
Was a Member of the New Jersey Technology Council.
Education includes undergraduate studies at Villanova University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-05 | 105,356 ( 0.02% ) | 237 051 $ | 2026-08-30 |
Scott Coiante active positions
| Companies | Position | Start |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Director of Finance/CFO | 2025-01-01 |
Former positions of Scott Coiante
| Companies | Position | End |
|---|---|---|
| AGILE THERAPEUTICS, INC. | Director of Finance/CFO | 2024-08-25 |
| APREA THERAPEUTICS, INC. | Director of Finance/CFO | 2023-01-29 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Director of Finance/CFO | 2022-12-31 |
| AGILE THERAPEUTICS, INC. | Director of Finance/CFO | 2019-08-04 |
Medarex, Inc.
 Medarex, Inc. BiotechnologyHealth Technology Provides antibody and oncology drug development services | Director of Finance/CFO | 2004-12-31 |
Training of Scott Coiante
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
94
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Medarex, Inc.
Medarex, Inc. BiotechnologyHealth Technology Provides antibody and oncology drug development services | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Lexicon Pharmaceuticals, Inc.
 Lexicon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Agile Therapeutics, Inc.
 Agile Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures hormonal contraceptive products | Health Technology |
Villanova University
 Villanova University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Jersey Technology Council
 New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services Provides business development, education and advocacy services | Commercial Services |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
- Stock Market
- Insiders
- Scott Coiante
